PT  - JOURNAL ARTICLE
AU  - Agan, Marie LittleFawn
AU  - Taylor, William R.
AU  - Young, Isaiah
AU  - Willis, William A.
AU  - New, Gari D.
AU  - Lair, Halee
AU  - Murphy, Anastasia
AU  - Marinelli, Anna
AU  - Juel, Md Ariful Islam
AU  - Munir, Mariya
AU  - Dornburg, Alex
AU  - Schlueter, Jessica
AU  - Gibas, Cynthia
TI  - Wastewater as a back door to serology?
AID  - 10.1101/2022.11.11.22282224
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2022.11.11.22282224
4099  - http://medrxiv.org/content/early/2023/10/20/2022.11.11.22282224.short
4100  - http://medrxiv.org/content/early/2023/10/20/2022.11.11.22282224.full
AB  - Wastewater surveillance is a powerful tool for monitoring the prevalence of infectious disease. Systems for wastewater monitoring were put in place throughout the world during the COVID-19 pandemic. These systems use viral RNA copies as the basis of estimates of COVID-19 cases in the sewershed area, thereby providing data critical for public health responses. However, the potential to measure other biomarkers in wastewater during outbreaks has not been fully explored. Here we report a novel approach for detecting specific human antibodies from wastewater. We measured the abundance of anti-SARS-CoV-2 spike IgG and IgA from fresh samples of community wastewater and from archived frozen samples dating from 2020-22. The assay described can be performed with readily available reagents, at a moderate per-sample cost. Our findings demonstrate the feasibility of noninvasive serological surveillance via wastewater, enabling a new approach to immunity-based monitoring of populations.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding was provided by the UNC-Charlotte Division of Research.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData produced and protocols used in the present study are included in full in the article. Authors will respond to any reasonable request for clarification or further information.